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Abstract 
Cerebrotendinous xanthomatosis is an autosomal recessive disorder of bile acid metabolism 
causing a range of progressive neurological symptoms. Even in the presence of the classical 
triad of neurological dysfunction, tendon xanthoma, and early onset cataracts, the diagnosis is 
often missed.  It can mimic more common conditions such as hereditary spastic paraparesis or 
multiple sclerosis, particularly when the phenotype is spinal xanthomatosis where the disease 
causes a spastic paraplegia.  Early recognition and initiation of chenodeoxycholic acid therapy 
may prevent irreversible neurological damage.  The introduction of next generation 
sequencing to screen for a large number of genetic disorders associated with progressive 
spastic paraparesis will allow earlier identification and initiation of treatment of these patients 
and their families, and will be particularly helpful in atypical cases such as the individual 
described in this case report. 
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Introduction 
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disease 
caused by mutations in the CYP27A1 gene which leads to a deficiency of the enzyme sterol 27-
hydroxylase.1  Subsequent dysfunction of chenodeoxycholic acid synthesis results in a build-up 
of precursor molecules: cholesterol and cholestanol. These become deposited in the central 
nervous system causing dementia, psychiatric disturbances, epilepsy, cerebellar syndromes, 
peripheral neuropathy and spastic paraparesis. Deposition in other tissues causes early-onset 
cataracts, tendon xanthomas, premature arteriosclerosis and osteoporosis.  Chronic diarrhoea 
can occur, probably due to impaired bile acid production.1  Identification is vital as treatment 
can potentially reverse the manifestations.  The introduction of genetic screening using next 
generation sequencing has the potential to identify previously unrecognised cases of CTX and 
other rare genetic diseases providing the opportunity for diagnosis and treatment.  
 
Case History 
A 27-year-old man presented with a 3-year history of spontaneous clonus, leg stiffness and 
falls. He had suffered from chronic diarrhoea from early childhood, the cause of which had 
remained uncertain despite extensive investigation. He also had a history of depression and 
had suffered from urinary frequency for several years.  He reported a normal childhood 
development and average school performance. His paternal aunt who lived in another part of 
the country was reported to suffer from multiple sclerosis and his paternal cousin was 
described as having an abnormal gait.  Neither parent suffered from any neurological disorder. 
 
Neurological examination demonstrated a few beats of unsustained gaze evoked nystagmus on 
lateral gaze to both sides and a brisk jaw jerk. Fundoscopy was normal and there was no 
evidence of cataracts. His upper limbs were normal except for symmetrically brisk reflexes.  
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Examination of the lower limbs revealed pes cavus, considerably increased tone, sustained 
ankle clonus, diffuse hyper-reflexia and extensor plantar responses. There was no evidence of 
tendon xanthomas and no other cerebellar signs. Examination of his father also revealed pes ǡǤǯ
mother was normal.  
 
Investigations and disease course 
Routine blood tests and magnetic resonance imaging of the brain and whole spine were 
normal.  Cerebrospinal fluid examination showed an elevated protein level of 954mg/L but a 
normal white cell count and oligoclonal bands were absent.   
 
The patient was given a diagnosis of hereditary spastic paraparesis (HSP). Genetic testing for 
the dominant HSP genes SPAST (SPG4), ATL1 (SPG3A) and REEP1 (SPG31) revealed no 
mutation.  He was followed up in clinic over the next 13 years during which time his symptoms 
gradually progressed and he became wheelchair dependent. He also developed reduced 
sensation to pinprick, joint position and vibration peripherally with depression of the ankle 
jerks, which had previously been brisk. He suffered from two episodes of depression requiring 
hospitalisation. 
 
In the process of establishing next generation sequencing equipment, the Sheffield Diagnostic 
Genetics Service (SDGS) screened stored samples from a group of patients with presumed HSP 
in whom a genetic diagnosis had not been established, for a panel of genes associated with 
motor system disorders.  Analysis of a subpanel of 40 genes associated with spastic paraplegia 
revealed this patient to be homozygous for a previously reported mutation in exon 6 of the 
CYP27A1 gene, c.1183C>T, predicted to result in the p.Arg395Trp (R395W) protein change.2  
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This mutation was confirmed by Sanger sequencing.  No significant variants were identified in 
any of the other 39 genes analysed.  The serum cholestanol level was then tested and found to 
be raised (112µmol/L, normal range <16) which confirmed the diagnosis of cerebrotendinous 
xanthomatosis. 
 
Discussion 
Hereditary spastic paraparesis  (HSP) is a genetically heterogeneous syndrome characterised 
by progressive lower extremity spasticity, often disproportionate to any degree of weakness.3 
A large number of genetic mutations have now been identified with a highly variable 
phenotype amongst carriers but de novo mutations are also possible and therefore the absence 
of a family history should not exclude the diagnosis.  As in our ǯ, HSP is often 
associated with urinary disturbance and can be associated with cerebellar signs, pes cavus and 
sensory symptoms due to dorsal column involvement or neuropathy.3 However, whilst a 
number of other atypical symptoms such as mental retardation, dementia, epilepsy, and 
cataracts may be seen in some types of HSP, chronic diarrhoea has not been reported and is a ǲǳ.3 
 
Typical cerebrotendinous xanthomatosis (CTX) can present with a variety of neurological 
features not dissimilar to those of HSP, with pyramidal signs (81%), cerebellar signs (56%), 
intellectual problems (57%), seizures (24%) and neuropathy (24%) in one case series, along 
with the classic signs of cataract (90%) and tendon xanthomas (45%).4  Chronic diarrhoea was 
reported in 33-50% of cases.4,5  Spinal xanthomatosis is a rarely described variant of CTX in 
which patients present with symptoms of corticospinal and dorsal column tract dysfunction 
without many of the additional classic features CTX and is typically milder in its disease 
course.6,7 In a series of seven patients with spinal xanthomatosis, only one patient had tendon 
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xanthomas and four gave a history of chronic diarrhoea but (unlike our patient) all had 
juvenile cataracts.6   Of these cases, three received incorrect initial diagnoses, including 
multiple sclerosis, cervical myelopathy and HSP. A further two cases of spinal xanthomatosis 
involving a progressive myelopathy without the classic features of CTX and normal MRI 
imaging have also been reported.7,8  In CTX, typical MRI findings of symmetrical cerebral and 
cerebellar white matter lesions are expected, but in spinal xanthomatosis MRI may 
demonstrate specific T2 weighted post-gadolinium MRI changes of extensive white matter 
pathology in the lateral and dorsal tracts of the spinal cord.6  The fact that these were seen 
using phased-array coils with sensitivity for intrinsic spinal cord lesions might explain why 
MRI appearances using standard technology may be normal.6,8  As the case described in this 
report demonstrates, normal MRI appearances should therefore not detract from a possible 
diagnosis of spinal xanthomatosis.  Diagnosis should be confirmed by measuring serum 
cholestanol and urinary bile alcohol levels and molecular genetic analysis for mutations in 
CYP27A1. 
 
Treatment with chenodeoxycholic acid (CDCA) replacement reduces serum cholestanol levels 
in CTX patients.9   In a series of 17 cases, after one year of treatment, there was significant 
clinical improvement with resolution of dementia (10 out of 13 cases), improvement or 
resolution of pyramidal and cerebellar signs  (13 out of 17) and resolution in neuropathy (6 
out of 7).9  The addition of simvastatin to CDCA was associated with a further reduction in 
cholestanol compared to CDCA alone, whilst also reducing levels of total and LDL cholesterol 
and increasing levels of HDL cholesterol.10  No additional clinical improvement were observed 
following a six-month course of the combination therapy compared to CDCA alone, but given 
that premature atherosclerosis and coronary artery disease have been reported, simvastatin 
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may convey a benefit in primary prevention of cardiovascular complications.10,11  Patients 
should also undergo lifestyle counselling to further reduce their cardiovascular risk. 
 
The diagnosis of the spinal form of CTX was made in this patient following next generation 
sequencing (NGS) of a panel of 41 genes associated with motor system disorders (Table 1).  
Validation data for the NGS technology used shows that both the test sensitivity and test 
specificity is >99%, with confidence intervals of 95% for both.  Hence, it is expected to detect 
all mutations other than large deletions or duplications.  However, work is currently underway 
to evaluate the use of NGS technology for dosage analysis and to increase the number of genes 
associated with motor system disorders that can be analysed.  To date 72 spastic gait disease-
loci and 55 spastic paraplegia genes (SPGs) have been identified, with all modes of inheritance 
described encompassing a very wide phenotype.12  New developments in genetic sequencing 
technology, combined with a gradual reduction in the cost of screening, will, in future, allow a 
molecular diagnosis to be established more frequently in this group of patients.  
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Table 1. Next generation sequencing gene panel for screening of HSP-like disorders 
 
 
  
Disease / Locus Gene 
SPG1  L1CAM 
SPG2  PLP1 
SPAX1  VAMP1 
SPAX4  MTPAP 
SPAX5 / SCA28  AFG3L2 
SPG3A  ATL1 
SPG4   SPAST 
SPG5A  CYP7B1 
SPG6  NIPA1 
SPG7  SPG7 
SPG8  KIAA0196 
SPG10  KIF5A 
SPG11  SPG11 
SPG12  RTN2 
SPG13  HSPD1 
SPG15  ZFYVE26 
SPG17  BSCL2 
SPG20  SPG20 
SPG21 (Mast syndrome)  SPG21 
SPG26  B4GALNT1 
SPG22  SLC16A2 
SPG28  DDHD1 
SPG30  KIF1A 
SPG31  REEP1 
SPG33  ZFYVE27 
SPG35  FA2H 
SPG46  GBA2 
SPG48  AP5Z1 
SPG53  VPS37A 
SPG54  DDHD2 
SPG55  C12orf65 
SPG56  CYP2U1 
IAHSP  ALS2 
CTX  CYP27A1 
ALS11  FIG4 
DYT5  GCH1 
FAD-SP PSEN1 
ARSACS  SACS 
ALS16  SIGMAR1 
DYT9  SLC2A1 
NBIA5 / SENDA  WDR45 
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Key points 
In patients with presumed HSP diagnosis is important to identify treatable causes, prevent 
complications and provide screening and genetic counselling for family members.  It is 
therefore important to consider the wider differential diagnosis in the many patients with an 
HSP-like syndrome in whom screening for the most common genetic mutations is negative, 
particularly where there are additional or atypical symptoms.  In the future, increasing 
identification of genetic mutations associated with HSP and improved access to next 
generation sequencing will increase the speed and likelihood of diagnosis and offer the 
opportunity for treatment in many more cases.  This is particularly pertinent in CTX where 
treatment has the potential to arrest or even reverse the disease.  Until genetic sequencing 
becomes standard practice however, it is important to emphasise that metabolic screening for 
cerebrotendinous xanthomatosis should be performed in all patients with two out of four of 
the following features: juvenile-onset cataracts, intractable diarrhoea, tendon xanthomas or 
progressive neurological symptoms, even when neuroimaging is normal.  
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